Dyne Therapeutics(DYN) Newsfilter·2025-01-09 12:30Company Overview - Dyne Therapeutics is a clinical-stage company focused on developing innovative therapeutics for genetically driven neuromuscular diseases [3] - The company leverages its FORCE™ platform to design targeted therapeutics that address delivery challenges to muscle tissue and the central nervous system [3] - Dyne has a broad pipeline including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), as well as a preclinical program for facioscapulohumeral muscular dystrophy (FSHD) [3] Upcoming Event - Dyne Therapeutics' president and CEO John Cox is scheduled to present at the 43rd Annual J P Morgan Healthcare Conference on January 15, 2025 at 10:30 a m PT (1:30 p m ET) [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days following the event [2]